Repligen Corp (RGEN)
NASDAQ:RGEN
Want to see RGEN full AI Analyst Report?
RGEN Stock Chart & Stats
$131.21
$0.11(0.07%)
At close: 4:00 PM EST
$131.21
$0.11(0.07%)
Day’s Range― - ―
52-Week Range$109.50 - $175.77
Previous CloseN/A
Volume111.19K
Average Volume (3M)882.42K
Market Cap
$6.96B
Enterprise Value$7.07B
Total Cash (Recent Filing)$784.53M
Total Debt (Recent Filing)$687.62M
Price to Earnings (P/E)199.2
Beta0.99
Next Earnings
Aug 04, 2026EPS Estimate
0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.91
Shares Outstanding56,407,740
10 Day Avg. Volume783,136
30 Day Avg. Volume882,418
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.38
Price to Sales (P/S)12.48
P/FCF Ratio98.13
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue9.26
Enterprise Value/Gross Profit18.43
Enterprise Value/Ebitda39.86
Forecast
1Y Price Target
$175.07Price Target Upside33.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)2
Revenue Forecast (FY)$823.02M
Bulls Say, Bears Say
Bulls Say
International Expansion And Key AccountsExpanded Asia-Pacific presence and a focused key-account strategy targeting large pharma and CDMOs increase international reach and create opportunities to deepen penetration in major customers.
Product Innovation And M&AAcquisition of a desktop analytics portfolio combined with multiple new product launches, including new chromatography resins and combined ATF/MAVERICK development, broadens the product mix and enhances cross-selling potential.
Revenue Momentum And DemandCompany delivered strong organic revenue growth and beat analyst estimates, reflecting sustained demand across Analytics and Proteins that can support continued top-line expansion.
Bears Say
Conservative Financial GuidanceFormal guidance that is framed conservatively may limit near-term upside by assuming muted end-market conditions and reducing investor expectations.
Customer Ordering DelaysOrdering delays from pharmaceutical customers who are evaluating MFN-related deals are creating demand headwinds that could slow revenue recognition.
Margin Guidance And PressureAdjusted margin guidance that comes in slightly below market expectations establishes a profit-margin floor but introduces near-term margin pressure and constrains earnings upside.
Repligen News
RGEN FAQ
What was Repligen Corp’s price range in the past 12 months?
Repligen Corp lowest stock price was $109.50 and its highest was $175.77 in the past 12 months.
What is Repligen Corp’s market cap?
Repligen Corp’s market cap is $6.96B.
When is Repligen Corp’s upcoming earnings report date?
Repligen Corp’s upcoming earnings report date is Aug 04, 2026 which is in 85 days.
How were Repligen Corp’s earnings last quarter?
Repligen Corp released its earnings results on May 05, 2026. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.384 by $0.096.
Is Repligen Corp overvalued?
According to Wall Street analysts Repligen Corp’s price is currently Undervalued.
Does Repligen Corp pay dividends?
Repligen Corp does not currently pay dividends.
What is Repligen Corp’s EPS estimate?
Repligen Corp’s EPS estimate is 0.45.
How many shares outstanding does Repligen Corp have?
Repligen Corp has 56,407,740 shares outstanding.
What happened to Repligen Corp’s price movement after its last earnings report?
Repligen Corp reported an EPS of $0.48 in its last earnings report, beating expectations of $0.384. Following the earnings report the stock price went up 6.26%.
Which hedge fund is a major shareholder of Repligen Corp?
Currently, no hedge funds are holding shares in RGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Repligen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$175.07 (33.43% Upside)
$175.07 (33.43% Upside)
Blogger Sentiment
Bullish
RGEN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.93%
12-Months-Change
Fundamentals
Return on Equity
2.46%
Trailing 12-Months
Asset Growth
2.76%
Trailing 12-Months
Company Description
Repligen Corp
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
RGEN Company Deck
RGEN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: the company reported healthy top-line growth ($194M, +15% reported, +11% organic), notable margin expansion (gross margin +180 bps, operating margin +160 bps), strong franchise performances (Analytics +50%+, Chromatography >25%, Proteins mid-teens), solid cash position ($785M), and raised adjusted EPS guidance. Management launched a transformation office targeting at least 1 point of annualized margin benefit by end of 2027 and announced a strategic OEM partnership in China. Key headwinds are mostly timing and structural: divestiture of a loss-making Polymem reduced revenue (~$7M), ATF/gene therapy customer timing moderated near-term growth (expected to rebound in 2027), some Q1 margin benefits may normalize, and there is execution risk around customer readiness for capital equipment and competition in China. Overall, positives (growth, margins, guidance, strategic initiatives, cash) materially outweigh the manageable lowlights tied to timing, one-off costs, and a small divestiture impact.View all RGEN earnings summariesRGEN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
RGEN Stock 12 Month Forecast
Average Price Target
$175.07
▲(33.43% Upside)
Technical Analysis
AptarGroup
―
Merit Medical Systems
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―
Ownership Overview
0.67% Insiders
41.59% Mutual Funds
11.97% Other Institutional Investors
23.83% Public Companies and
Individual Investors